Open AccessThe use of daptomycin for the treatment of infectious endocarditis: results of a multicenter study
Author(s) -
Yu.L. Shevchenko,
V.P. Tyurin,
Л.В. Попов,
В Г Гудымович,
Е.П. Павликова,
N. L. Bayandin,
Т.А. Федорова,
N.I. Rusanov,
Serafima Ya. Tazina
Publication year - 2017
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2017-95-4-328-332
Subject(s) - daptomycin , medicine , endocarditis , infective endocarditis , surgery , antibiotics , staphylococcus aureus , vancomycin , microbiology and biotechnology , biology , bacteria , genetics
Analysis of the results of daptomycin antibiotic therapy and surgical treatment of 37 patients with infective endocarditis (IE) admitted to three Moscow hospitals during 2012 to 2016 is presented. Primary endocarditis was diagnosed in 32.4% of the cases. The secondary forms of the disease dominated by endocarditis following cardiac surgery (29.7%) including valve prosthetics and implantation of pacemaker/cardioverter-defibrillator (PM/CVD). Positive reaction in 2 or more blood cultures was observed in 73% of the patients with the prevalence of Staphylococcus aureus (27%). Vegetation at TT and emergency echocardiography was documented in 89.2% of the patients, fibrous ring or leaflet abscesses in 24.3%). All patients were treated with daptomycin at an average dose of 6,7 ± 0,7 mg/kg b w. The duration of therapy was 26,7 ± 9,8 days. Surgical treatment was given to 48.6% of the patients including PM/CVD replacement in 5.4%. Surgical mortality was absent. Hospital mortality amounted to 13.5%. The use of daptomycin in combination with surgical treatment can significantly improve the results of treatment of this serious disease.